Key result
Active cancer in non-high-risk PE is linked to significantly higher troponin I despite similar RV dysfunction.
Why the study?
The study aimed to compare PE location, clot burden, right ventricular dysfunction, D-dimer, troponin I levels, and DVT presence between patients with and without cancer diagnosed with non-high risk PE.
Does the presence of cancer affect clot burden, right ventricular dysfunction, or biomarker levels in patients with non-high risk pulmonary embolism?
Observational (n=71)
No
Does the presence of cancer affect clot burden, right ventricular dysfunction, or biomarker levels in patients with non-high risk pulmonary embolism?
In non-high risk pulmonary embolism, concurrent cancer is associated with higher cardiac troponin I levels but not with increased clot burden or right ventricular dysfunction.
Answers are grounded in this paper and cite their sources.
May confound troponin-based risk stratification in non-high-risk PE with cancer; hypothesis-generating for mechanisms beyond clot burden.
OBJECTIVE: This study aimed to compare the pulmonary embolism (PE) location and clot burden on computed tomography pulmonary angiography (CTPA), the degree of right ventricular dysfunction (RVD), D-dimer, and cardiac troponin I (cTnI) levels, and the presence of a lower extremity deep venous thrombosis (DVT) in patients with and without cancer diagnosed with a non high risk pulmonary embolism (PE). METHOD: We calculated Miller score for each patient for clot burden. The location of PE was also evaluated at CTPA. D-dimer and cardiac cTnI levels were measured. Patients had echocardiography for RVD and lower extremity color flow Doppler ultrasonography for DVT. RESULTS: The study included 71 patients with PE. The patients were divided into two groups according to the presence of cancer. There was no statistically significant difference for D-dimer levels (P=0.15), PE location (p=0.67), clot burden (P=0.34), RVD (P=0.28) and DVT (P=0.33) between groups (P=0.15). Cancer patients diagnosed as PE had statistically significantly higher levels of cTnI than those who were diagnosed as PE without cancer (P=0.03). CONCLUSION: There was no significant difference between patients diagnosed as PE with and without cancer in terms of D-dimer levels, clot burden and emboli location, RVD and DVT. cTnI levels were higher in non-high risk PE patients with cancer than these patients without cancer.
No takes yet. Share an insight, caveat, or question.
Çalışkan et al. (2021) conducted an observational in Non-high risk pulmonary embolism (n=71). Active cancer vs. No cancer was evaluated on Cardiac troponin I (cTnI) levels (ng/L) (p=0.03). In patients with non-high risk pulmonary embolism, the presence of active cancer was associated with higher cardiac troponin I levels compared to patients without cancer, with no significant differences in clot burden or right ventricular dysfunction.
Synapse has enriched 10 related papers. Consider them for comparative context: